In Plain English:
Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), launched in 2000 by French company Sederma. It is a five-amino-acid sequence (Lys-Thr-Thr-Lys-Ser) derived from the C-terminal region of type I procollagen, attached to a 16-carbon palmitic acid tail that carries it through the stratum corneum. Once in the dermis, skin esterases cleave the palmitoyl chain and free KTTKS signals fibroblasts — the same signal the body uses when collagen is degrading — triggering new collagen I, III, and IV, fibronectin, and hyaluronic acid production. Matrixyl 3000 is a later Sederma blend combining Pal-GHK (palmitoyl tripeptide-1) and Pal-GQPR (palmitoyl tetrapeptide-7). The strongest human evidence is a 93-woman double-blind split-face RCT (Robinson 2005) showing significant wrinkle reduction at just 3 ppm over 12 weeks. Effect sizes are real but modest — smaller than well-formulated retinol, larger than most other peptide cosmetics. No irritation or systemic safety signals in 25 years of commercial use.
Research Maturity
Moderate Human (~85 PubMed-indexed publications on Matrixyl / palmitoyl pentapeptide-4 (Pal-KTTKS)+ Studies)
Focus
Cosmetic Wrinkle Appearance
Dermal Matrix Support
Skin Aging
Origin
Synthetic lipopeptide. KTTKS sequence first identified by Katayama et al. (1993) as the minimal collagen-stimulating fragment of type I procollagen C-terminal propeptide. Commercialised by Sederma SAS (France) in 2000 as the first clinically validated topical anti-aging peptide. Won the IFSCC 25-Year Most Influential Innovation Award in 2015. Matrixyl 3000 (Pal-GHK + Pal-GQPR blend) launched circa 2005.
Mechanism
Acts as a matrikine — mimics ECM degradation fragments that fibroblasts interpret as a damage signal. Binds cell-surface receptors on dermal fibroblasts, activates TGF-β signalling (Tsai et al., dose-dependent), and upregulates transcription of collagen I, III, IV, fibronectin, and glycosaminoglycans including hyaluronic acid. Simultaneously inhibits MMP (matrix metalloproteinase) collagenase activity, slowing ECM degradation. Palmitoylation achieves 100–1000-fold greater skin permeability versus unmodified KTTKS: penetrates to stratum corneum 4.2 µg/cm², epidermis 2.8 µg/cm², dermis 0.3 µg/cm² (Choi et al., 2014). Induces epidermal thickening and suppresses excess GAG accumulation associated with aged skin.
Outcome
Robinson 2005 (n=93, DB-RCT, 12 weeks, 3 ppm): significant reduction in wrinkle/fine-line length vs. placebo, expert-graded and subject-rated. Sederma 28-day study (0.005%): 18% wrinkle depth reduction, 37% fold thickness reduction, 21% skin roughness improvement. Aruan 2023 (n=21, DB-RCT, 8 weeks): palmitoyl pentapeptide-4 superior to acetylhexapeptide-3 and placebo for crow's feet in Asian subjects. Kachooeian 2022 (n=42 rats, 21 days): wound healing 63.5% → 81.8% vs. negative control; patch delivery superior to cream. Sederma-sponsored 4-month data: 45% reduction in deep wrinkle area, ~20% increase in skin tonicity.
